A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (ADV RCC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hudes, G
  • Carducci, M
  • Tomczak, P
  • Duther, J
  • Figlin, R
  • Kapoor, Anil
  • Staroslawska, E
  • O'Toole, T
  • Park, Y
  • Moore, L

publication date

  • January 1, 2006